Detalles de la búsqueda
1.
Efficacy of solifenacin for overactive bladder symptoms, symptom bother, and health-related quality of life in patients by duration of self-reported symptoms: a secondary analysis of the VIBRANT study.
Urol Nurs
; 32(1): 38-46, 50, 2012.
Artículo
en Inglés
| MEDLINE | ID: mdl-22474864
2.
Cardiac sodium channel inhibition by lamotrigine: In vitro characterization and clinical implications.
Clin Transl Sci
; 15(8): 1978-1989, 2022 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-35579204
3.
Solifenacin treatment in men with overactive bladder: effects on symptoms and patient-reported outcomes.
Aging Male
; 13(2): 100-7, 2010 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-20001469
4.
Diary and patient-reported outcomes in patients with severe overactive bladder switching from tolterodine extended release 4 mg/day to solifenacin treatment: An open-label, flexible-dosing, multicentre study.
Clin Drug Investig
; 29(5): 305-16, 2009.
Artículo
en Inglés
| MEDLINE | ID: mdl-19366272
5.
Efficacy of solifenacin in patients previously treated with tolterodine extended release 4 mg: results of a 12-week, multicenter, open-label, flexible-dose study.
Clin Ther
; 30(10): 1766-81, 2008 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-19014833
6.
Albiglutide efficacy and safety in the Latino/Hispanic subpopulation for the integrated phase III program.
Postgrad Med
; 129(8): 849-857, 2017 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-29083275
7.
Efficacy and tolerability of solifenacin in patients aged ≥ 65 years with overactive bladder: post-hoc analysis of 2 open-label studies.
Postgrad Med
; 123(1): 94-104, 2011 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-21293089
8.
Efficacy of Solifenacin on Overactive Bladder Symptoms, Symptom Bother, and Other Patient-Reported Outcomes in Subjects With or Without Incontinence: A Post Hoc Analysis of Data From VIBRANT.
Female Pelvic Med Reconstr Surg
; 17(1): 24-9, 2011 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-22453669
9.
Impact of solifenacin on diary-recorded and patient-reported urgency in patients with severe overactive bladder (OAB) symptoms.
Curr Med Res Opin
; 26(10): 2277-85, 2010 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-20707767
10.
Efficacy of Solifenacin on Symptom Bother and Health-Related Quality of Life in Patients With Acute, Early Chronic, and Late Chronic Overactive Bladder: Secondary Analysis of Data From the VOLT Study.
Female Pelvic Med Reconstr Surg
; 16(6): 320-6, 2010 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-22453614
11.
Treatment with solifenacin increases warning time and improves symptoms of overactive bladder: results from VENUS, a randomized, double-blind, placebo-controlled trial.
Urology
; 73(1): 14-8, 2009 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-18995887
12.
Patient-reported most bothersome symptoms in OAB: post hoc analysis of data from a large, open-label trial of solifenacin.
Int Urogynecol J Pelvic Floor Dysfunct
; 20(6): 667-75, 2009 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-19434385
13.
Solifenacin for overactive bladder: patient-reported outcomes from a large placebo-controlled trial.
Postgrad Med
; 121(5): 151-8, 2009 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-19820284
14.
Solifenacin at 3 years: a review of efficacy and safety.
Postgrad Med
; 120(2): 85-91, 2008 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-18654073
Resultados
1 -
14
de 14
1
Próxima >
>>